Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
WL Conte, L Golzarri-Arroyo�- Multiple sclerosis and related disorders, 2022 - Elsevier
Background and objectives B-cell-depleting therapies may affect the development of a
protective immune response following vaccination against SARS-CoV-2. It is important to�…
protective immune response following vaccination against SARS-CoV-2. It is important to�…
[HTML][HTML] Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
JD Katz, AJ Bouley, RM Jungquist, EA Douglas…�- Multiple Sclerosis and�…, 2022 - Elsevier
Background The COVID-19 epidemic raises important questions about the efficacy of
vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been�…
vaccines for people treated with ocrelizumab, an anti-CD20 therapy. Ocrelizumab has been�…
Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab
Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific�…
response following vaccination. Understanding the ability to develop vaccine-specific�…
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: implications for SARS-CoV-2 vaccinations in multiple sclerosis
Background Ocrelizumab maintains B-cell depletion via six-monthly dosing. Whilst this
controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2�…
controls relapsing multiple sclerosis, it also inhibits seroconversion following SARS-CoV-2�…
[HTML][HTML] Long-term immune response profiles to SARS-CoV-2 vaccination and infection in people with multiple sclerosis on anti-CD20 therapy
C Woopen, M Dunsche, GK Al Rahbani, A Dillenseger…�- Vaccines, 2023 - mdpi.com
Our objective was to analyze longitudinal cellular and humoral immune responses to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in people with multiple�…
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in people with multiple�…
[HTML][HTML] Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple�…
S R�uber, A Willison, M Korsen, T K�lsche…�- Frontiers in�…, 2022 - frontiersin.org
Introduction Given the varying severity of coronavirus disease 2019 (COVID-19) and the
rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2)�…
rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2)�…
Factors associated with serological response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with rituximab
A Tolf, A Wiberg, M M�ller, FH Nazir…�- JAMA network�…, 2022 - jamanetwork.com
Importance B-cell–depleting monoclonal antibodies are widely used for treatment of multiple
sclerosis but are associated with an impaired response to vaccines. Objective To identify�…
sclerosis but are associated with an impaired response to vaccines. Objective To identify�…
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case�…
Aim To determine the influence of high-efficacy disease modifying therapy (DMT) on the
development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with�…
development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with�…
Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: a case-control study
WL Conte�- Multiple sclerosis and related disorders, 2021 - Elsevier
Objective Ocrelizumab (OCR) is a monoclonal antibody directed at B-cells that is FDA
approved for treatment of RRMS and PPMS. Prior studies have raised concerns about�…
approved for treatment of RRMS and PPMS. Prior studies have raised concerns about�…
Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies
Objectives To determine anti-SARS-Cov2 antibodies and T-cell immunity in convalescent
people with multiple sclerosis (pwMS) and/or pwMS vaccinated against Covid-19�…
people with multiple sclerosis (pwMS) and/or pwMS vaccinated against Covid-19�…